BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
San Francisco, California-- (Newsfile Corp. - February 20, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase ...
ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioAge Labs, Inc. Investors to Secure Counsel ...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...
FierceBiotech2 天
Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed ...
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...
Le Lézard1 天
Kirby McInerney LLP Urges Investors in BioAge Labs, Inc. (BIOA) to Inquire About Their ...
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired ...